UKRI Call for Applications: Malaria vaccine implementation studies in Africa
The UK Research and Innovation (UKRI) is inviting applications for the Applied Global Health Research Board (AGHRB): Malaria vaccine implementation studies in Africa.
In 2021 the World Health Organization (WHO) approved the world’s first malaria vaccine: RTS,S. WHO then approved the R21/Matrix M vaccine in 2023. In rapid succession two malaria vaccines had been approved for use in children. The R21 and RTS,S vaccines will be a vital component of future malaria control programmes, with RTS,S roll-out starting in nine African countries this year.
Research is urgently needed to understand the optimal strategies for vaccine roll-out and to ensure that they are deployed in the most effective and equitable way for population health benefit.
Eligibility:
- be eligible as an individual
- be based at either an eligible UK research organisation, or based in a:
- research organisation in a low or middle-income country (LMIC), with degree-awarding powers recognised by the government in which the organisation is based
- research-focused institute based in an LMIC either funded by the government of the country in which the organisation is based, or by a not-for-profit organisation
- research-focused not-for-profit organisation based in an LMIC with dedicated research capacity
You are not eligible to apply if:
- you are based in a high-income country (does not include UK project leads, who are eligible), or in India, you are not eligible to be project lead, but may be eligible to be project co-lead (international)
- you are based in China
Funding details:
- Duration of up to five years
Important dates
-
Pre application deadline – June 3, 2024
- Invited full application deadline – July 16, 2024
Read more here.
